• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组粒细胞巨噬细胞集落刺激因子治疗难治性再生障碍性贫血患者的骨髓变化

Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF.

作者信息

Naeim F, Champlin R, Nimer S

机构信息

Department of Pathology, UCLA School of Medicine 90024.

出版信息

Hematol Pathol. 1990;4(2):79-85.

PMID:2197266
Abstract

The morphologic changes in the bone marrow of eight patients with refractory aplastic anemia who received 4 or more weeks of granulocyte macrophage-colony-stimulating factor (GM-CSF) are described. All eight patients demonstrated a continuous rise in the absolute number of neutrophils, eosinophils, and monocytes over the first four weeks of therapy. Bone marrow examination revealed a progressive increase in bone marrow cellularity in all patients except one. An increase in myeloid: erythroid ratio was seen with progressive maturation of granulocytic cells. Neutrophilic and eosinophilic myelocytes were the most prominent cells. The percentage of myeloblasts and promyelocytes did not increase significantly, and the proportions of postmitotic granulocytic cells did not change either. No significant morphologic changes were noted in the basophilic, erythroid, and megakaryocytic series. The most prominent topographic observation in the bone marrow during GM-CSF therapy was the frequent clustering of myeloid cells close to the bone trabeculae. The periosteal localization of myeloid precursors may reflect a higher concentration of stem cells and/or stromal cells in the bone marrow adjacent to the bone trabeculae or a higher concentration of growth factors. Careful morphologic examination of bone marrow in CSF clinical trials will provide useful information regarding the in vivo effects of these growth factors, and will aid in the development of a rational approach to combining them for therapy.

摘要

本文描述了8例接受粒细胞巨噬细胞集落刺激因子(GM-CSF)治疗4周或更长时间的难治性再生障碍性贫血患者骨髓的形态学变化。所有8例患者在治疗的前四周中性粒细胞、嗜酸性粒细胞和单核细胞的绝对数量持续上升。骨髓检查显示,除1例患者外,所有患者的骨髓细胞增多症均呈进行性增加。随着粒细胞的逐渐成熟,髓系与红系比例增加。嗜中性和嗜酸性髓细胞是最突出的细胞。原粒细胞和早幼粒细胞的百分比没有显著增加,有丝分裂后粒细胞的比例也没有变化。嗜碱性粒细胞系、红系和巨核细胞系未观察到明显的形态学变化。GM-CSF治疗期间骨髓最显著的地形学观察结果是髓系细胞频繁聚集在骨小梁附近。髓系前体细胞的骨膜定位可能反映了骨小梁附近骨髓中干细胞和/或基质细胞的浓度较高,或者生长因子的浓度较高。在CSF临床试验中对骨髓进行仔细的形态学检查将为这些生长因子的体内效应提供有用信息,并有助于制定合理的联合治疗方法。

相似文献

1
Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF.重组粒细胞巨噬细胞集落刺激因子治疗难治性再生障碍性贫血患者的骨髓变化
Hematol Pathol. 1990;4(2):79-85.
2
Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor.重组人粒细胞巨噬细胞集落刺激因子对再生障碍性贫血患者骨髓造血的刺激作用。
N Engl J Med. 1988 Dec 22;319(25):1628-34. doi: 10.1056/NEJM198812223192503.
3
Serum colony stimulating factors in patients undergoing bone marrow transplantation: enhancing effect of recombinant human GM-CSF.
Behring Inst Mitt. 1988 Aug(83):289-300.
4
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Behring Inst Mitt. 1988 Aug(83):149-53.
5
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.自体骨髓移植后,人骨髓髓系祖细胞对单独使用粒细胞集落刺激因子以及联合白细胞介素-3进行体内治疗的增殖反应。
Exp Hematol. 1995 Dec;23(14):1520-6.
6
Human recombinant hemopoietic growth factors G-CSF and GM-CSF: first results of clinical trials.人重组造血生长因子G-CSF和GM-CSF:临床试验的初步结果。
Nouv Rev Fr Hematol (1978). 1989;31(2):99-101.
7
Use of granulocyte-macrophage colony-stimulating factor in patients with malignancy and bone marrow failure.粒细胞巨噬细胞集落刺激因子在恶性肿瘤和骨髓衰竭患者中的应用。
Int J Cell Cloning. 1990 Jan;8 Suppl 1:303-12; discussion 312-3. doi: 10.1002/stem.5530080729.
8
A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.一项关于通过静脉推注或持续输注给予重组粒细胞巨噬细胞集落刺激因子进行治疗的I期研究。
Behring Inst Mitt. 1988 Aug(83):125-33.
9
Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.接受纯化重组人粒细胞巨噬细胞集落刺激因子I期临床试验患者的骨髓造血祖细胞/前体细胞的生长特性
Exp Hematol. 1988 Aug;16(7):594-602.
10
Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors.重组人白细胞介素3对人造血祖细胞增殖和分化的刺激作用。与重组人粒细胞-巨噬细胞集落刺激因子和粒细胞集落刺激因子的比较及相互作用。
Exp Hematol. 1989 Feb;17(2):191-7.

引用本文的文献

1
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.重组粒细胞-巨噬细胞集落刺激因子(rGM-CSF):其药理特性及在骨髓抑制管理中的潜在作用综述
Drugs. 1992 Apr;43(4):516-560. doi: 10.2165/00003495-199243040-00008.